key: cord-0950967-f6qsq4kp
authors: Bouland, Andrew J.; March, Juan Alberto
title: Invited Editorial: Characteristics and outcomes of adverse events following COVID‐19 vaccination
date: 2021-09-28
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12566
sha: bd53f5b19118e947811fbf0bf45ebe0650a64738
doc_id: 950967
cord_uid: f6qsq4kp

nan

In this issue, an article by Kewan et al, 1 More importantly, the authors point out that they observed higher mortality rates among non-vaccinated patients presenting to the ED, in addition to demonstrating that vaccinated individuals had a lower mortality rate (2.2%) than the unvaccinated (2.6%). The vaccinated in this study also had lower mortality rates than historical data, which noted a mortality rate of 8.3% at 1 month and 17.2% at 6 months in patients ages 65 years or older. 4 The 41 patients in this study who died after vaccination had complex medical histories and likely died of causes unrelated to the vaccination, including several who had cancer diagnoses and died while on comfort care. This study supports previous studies showing that the benefits of the vaccine far outweigh the risks of adverse effects of getting the disease. 5, 6 According to the most recent data from the Center for Disease Control at the time this article was written, the weekly rate of hospitalization was 0.1 per 100,000 among the vaccinated compared to 2.52 per 100,000 among the unvaccinated, whereas the weekly rate of death was 0.04 per 100,000 among

Characteristics and outcomes of adverse events following Covid-19 vaccination

Correlations genuine and spurious in peason and Yule

Trends in Emergency Department Visits

Association of emergency clinicians' assessment of mortality risk with actual 1-month mortality among older adults admitted to the hospital

The impact of vaccination on COVID-19 outbreaks in the United States

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

The White House

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting